Akari Therapeutics, Plc
AKTX
$10.73
$1.2112.71%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -290.15% | -40.46% | -121.07% | 74.93% | 33.44% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,026.52% | 2,050.96% | 8,127.12% | -254.41% | 1,210.11% |
| Change in Net Operating Assets | 47.62% | -98.70% | -142.72% | -120.27% | -64.52% |
| Cash from Operations | -15.72% | -43.17% | -42.35% | 33.47% | 46.83% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 73.74% | 87.46% | 39.88% | 35.35% | -139.07% |
| Issuance of Common Stock | -92.90% | 54.97% | -- | -53.98% | 53.09% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -97.52% | 167.41% | 528.22% | -56.45% | 40.89% |
| Foreign Exchange rate Adjustments | -- | -100.00% | -250.00% | 300.00% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -14,223.53% | 558.35% | 88.24% | -95.50% | 99.33% |